KUALA LUMPUR (May 25): IHH Healthcare Bhd (KL:IHH) said its operations in Türkiye remain unaffected by the ongoing Middle East conflict, with hospitals continuing to run at full capacity, according to group chief executive officer Dr Prem Kumar Nair.

The group operates in Türkiye primarily through Acibadem Healthcare Group, in which it holds a 90% stake.

“Our operations there are running as normal, at full capacity. There may be some impact on patient inflows from the Middle East but this is mitigated by a diversified international patient base, including Europe,” he told a press conference held after the group’s annual general meeting on Monday.

“Türkiye continues to grow and remains a significant contributor to our business. We will continue to evaluate opportunities in the market,” he added.

According to IHH’s annual report, Türkiye and Europe combined are the group’s largest revenue contributor, accounting for about one-third of FY2025 (financial year ended Dec 31) revenue, followed by Singapore (23%), Malaysia (19%) and India (16%).

The annual report noted that Türkiye’s ageing population continues to drive demand for higher-acuity and more complex care.

To meet this, IHH is expanding capacity through acquisitions and hospital upgrades, including Bayindir Hospitals, the expansion of Acibadem Kent Hospital and the opening of the 127-bed Acibadem Kartal Hospital. The group is also strengthening Acibadem’s position as a preferred provider for both local and international patients.

Across Europe, demand is rising on ageing populations and greater healthcare awareness, and IHH continues to pursue earnings-accretive expansion opportunities in the region.

Shares of IHH Healthcare closed unchanged at RM8.96 on Monday, giving it a market capitalisation of RM79.17 billion.

Read also:
IHH doubles down on tech, turns to generic drugs amid rising cost pressures